EMA

The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.

Having its own priority review vouchers could serve as an important pull incentive for neglected disease R&D in Europe, although the unpredictable nature of the vouchers may deter some investors.